Sponsored By
.png)
About this award
Now in its 18th year, the Scrip Awards brings together over 400 industry leaders to celebrate and recognise the very best innovations and achievements in global biopharma. Winners will be celebrated across 15 categories, covering a full spectrum of advancements, from Best New Drug, Community Partnership of the Year, Clinical Advance of the Year and Best Contract Research Organisation.
All Awards entries will be carefully reviewed by an independent Judging Panel - a group of senior industry experts from around the world, handpicked for their experience and objectivity. This prestigious annual event of networking and celebration will incorporate a gala black-tie dinner and Awards ceremony, on Wednesday 30 November at the Royal Lancaster Hotel, London.
Key details
Ceremony, Wednesday, 30 November, 2022
Free to Enter
Royal Lancaster, London
The Best New Drug Award recognises excellence in pharmaceutical development. Launching innovative new products is the most important function of the industry, and a successful new drug launch marks the culmination of years of risky and expensive R&D.
WINNER:
Immunocore’s Kimmtrak (tebentafusp) for metastatic uveal melanoma
Watch the winners interview here
NOMINEEES:
- Agios Pharmaceuticals’ Pyrukynd (mitapivat) for pyruvate kinase deficiency
- Argenx’s Vyvgart (efgartigimod alfa) for generalized myasthenia gravis
- Immunocore’s Kimmtrak (tebentafusp) for metastatic uveal melanoma
- Legend Biotech/Janssen Biotech’s Carvykti (ciltacabtagene autoleucel) for multiple myeloma
- Mirum Pharmaceuticals’ Livmarli (maralixibat) for cholestatic pruritus in patients with Alagille syndrome
- Servier Pharmaceuticals’ Tibsovo (ivosidenib tablets) for cholangiocarcinoma with an IDH1 mutation
This Award seeks to recognise success in a clinical trial of a new drug product (biological or chemical) which is expected to lead to an advance in healthcare. This might include the first demonstration of a clear clinical effect for a new drug in an area of unmet medical need, a pivotal study of a new drug with a breakthrough mechanism of action, or a major study of a potential new or expanded indication for an already marketed product.
WINNER:
Daiichi Sankyo and AstraZeneca’s Phase III DESTINY-Breast04 trial of Enhertu in breast cancer
Watch the winners interview here
NOMINEES:
- Boehringer Ingelheim and Eli Lilly’s Phase III EMPEROR-Preserved trial of Jardiance in heart failure
- Daiichi Sankyo and AstraZeneca’s Phase III DESTINY-Breast04 trial of Enhertu in breast cancer
- Intellia Therapeutics’ Phase Itrial of NTLA-2001for transthyretin amyloidosis
- Janssen Oncology’s Phase I/II MajesTEC-1 study of teclistamab in multiple myeloma
- Lumosa Therapeutics’ Phase IIa study of LT3001 for stroke
- Servier’s Phase III AGILE trial of Tibsovo in IDH1-mutated AML
The biotech industry’s entrepreneurial spirit and cutting-edge science have transformed the research and development of medicines in the past few decades. This Award honours outstanding achievement by biotech companies
WINNER:
Moderna
Watch the winners interview here
NOMINEES:
- Bicycle Therapeutics
- Immunocore
- Moderna
- Qlaris Bio
- Redx Pharma
- SparingVision
Scrip’s China Biopharma Leadership Award reflects on the rapid maturing of China’s biopharma sector - thanks to the development of Homegrown biopharma companies, CDMOs, and increasing investment from global multinational biopharma companies. The category seeks to reward firms that have shown leadership in developing China’s biopharma sector through significant commercial and R&D activity, and by helping patients access new treatments, through new launches and successful negotiations with China’s healthcare payers and clinical leaders.
WINNER:
BeiGene China
NOMINEES:
To enter this category, please answer the following:
- Anticancer Bioscience
- BeiGene China
- Brii Biosciences
- Clover Biopharmaceuticals
- Everest Medicines
Scrip’s Executive of the Year Award is designed to acknowledge excellence in the leadership of large and small pharmaceutical and biotechnology companies.
WINNER:
Executive Of The Year – Companies with a market cap >$7bn
Stéphane Bancel, Chief Executive Officer of Moderna
Executive Of The Year – Private companies and those with a market cap <$7bn
Michael M Morrissey, President and Chief Executive Officer of Exelixis
NOMINEES:
Executive Of The Year – Companies with a market cap >$7bn
- Stéphane Bancel, Chief Executive Officer of Moderna
- Yvonne Greenstreet, Chief Executive Officer of Alnylam Pharmaceuticals
- Ying Huang, Chief Executive Officer of Legend Biotech
- Husseini Manji, Global Head of Johnson & Johnson Science for Minds
- Christi Shaw, Chief Executive Officer of Kite, a Gilead Company
- Jan van de Winkel, President & Chief Executive Officer of Genmab
Executive Of The Year – Private companies and those with a market cap <$7bn
- Renée Aguiar-Lucander, Chief Executive Officer of Calliditas Therapeutics
- Stéphane Boissel, Chief Executive Officer and Chairman of SparingVision
- Scott Braunstein, Chief Executive Officer of Marinus Pharmaceuticals
- Bahija Jallal, Chief Executive Officer of Immunocore
- John Leonard, President and Chief Executive Officer of Intellia Therapeutics
- Michael M Morrissey, President and Chief Executive Officer of Exelixis
Licensing is vital both in helping to keep pharma’s pipelines replenished and in generating income for smaller firms. Deals considered here are those that involve the licensing of a particular drug, project or group of drugs/projects from one company to another for further development and/ or marketing.
WINNER:
GSK and Alector for the development and commercialization of AL001 and AL101for neurodegenerative diseases
Watch the winners interview here
NOMINEES:
- Accord Healthcare with Myovant Sciences to commercialize Orgovyx(relugolix) for advanced hormone-sensitive prostate cancer
- AstraZeneca and Ionis Pharmaceuticals for the development and commercialization of eplontersen for TTR amyloidosis
- GSK and Alector for the development and commercialization of AL001 and AL101for neurodegenerative diseases
- iTeos and GSK for the development and commercialization of EOS-448 (GSK4428859A) for solid tumors
- RQ Biotechnology and AstraZeneca for novel monoclonal antibodies targeting SARS-CoV-2
- Sunovion Pharmaceuticals (Sumitomo Pharma) and Otsuka Pharmaceutical to jointly develop and commercialize ulotaront, non-racemic amisulpride, SEP-378614 and SEP-380135
The Award for the Best Contract Research Organization acknowledges the critical role that CROs play in drug development. Outsourcing is vital as the pharmaceutical industry seeks to benefit more and more from these specialist companies’ experience in handling all aspects of clinical trials and other research.
WINNER:
ICON
Watch the winners interview here
NOMINEES:
- Altasciences
- CMIC Group
- ICON
- IQVIA
- Novotech
- Parexel
- PPD, Part of Thermo Fisher Scientific
- Syneos Health
The Award for the Best Contract Research Organisation acknowledges the critical role that CROs play in drug development. Outsourcing is vital as the pharmaceutical industry seeks to benefit more and more from these specialist companies’ experience in handling all aspects of clinical trials and other research.
WINNER:
Veramed
Watch the winners interview here
NOMINEES:
- Cellomatics Biosciences
- CluePoints
- Crown Bioscience
- MAC Clinical Research
- Medical Research Network
- MMS Holdings
- PHASTAR
- Veramed
Scrip’s Best Partnership Alliance Award recognises the importance of pharmaceutical and/ or biotech companies working together to develop new medicines. This category seeks to reward innovative partnerships between companies in which they share the risks and rewards inherent in developing new drugs.
WINNER:
GRAIL and AstraZeneca for the research, development and commercialization of companion diagnostic assays for early-stage cancer
Watch the winners interview here
NOMINEES:
- Amgen and Arrakis Therapeutics for the discovery of RNA degraders
- GRAIL and AstraZeneca for the research, development and commercialization of companion diagnostic assays for early-stage cancer
- Merck KGaA and Amphista Therapeuticsto discover and develop small-molecule protein degraders in oncology and immunology indications
- Recursion and Roche/Genentech to use Recursion’sAI Operating System and Maps of Biologyto identify novel biological relationships in neuroscience and oncology
- Sanofi and IGM Biosciencesfor engineered IgM antibodies in oncology and immunology/inflammationtargets
- SparingVision and Intellia Therapeuticsto develop novel genomic medicines using CRISPR/Cas9 technology for ocular diseases
This Scrip Award seeks to reward successful and creative fundraising by pharma and biotech companies. The investment can come in a variety of guises from grants and public private partnership deals to venture fundraising and public offerings but should be earmarked for use in drug discovery and/or development.
Winner:
SalioGen Therapeutics’$130m Series B financing
NOMINEES:
- Engitix Therapeutics’ $54m Series A financing
- Mestag Therapeutics’ $45m seed funding
- Microbiotica’s£50m Series B financing
- OMass Therapeutics’ $100m Series B financing
- Precirix’s€80m Series B financing
- SalioGen Therapeutics’$130m Series B financing
This category will acknowledge and celebrate the outstanding scientific or technological breakthrough which the judging believes has the potential to be transformative in the discovery or development of new medicines.
Winner:
Orca Bio’s Orca-Tcell therapy
NOMINEES:
- 3DBio’s AuriNovo patient-matched, 3D-bioprinted living tissue ear implant
- BenevolentAI’sBenevolent Platform with Benevolent Knowledge Graph
- Evonetix’s desktop platform for DNA synthesis
- Nucleome Therapeutics’ genome dark matter platform technology
- Orca Bio’s Orca-Tcell therapy
- Quris BioAI Clinical Prediction Platform
The Pharma Company of the Year Award honours outstanding achievements by pharmaceutical companies over the qualifying 12 months between 1 June 2021 - 30 June 2022.
Winner:
Novo Nordisk
Watch the winners interview here
NOMINEES:
The winner of this Award will be an exceptional individual with a consistent history of service, above and beyond the call of duty, throughout their career. This prestigious international Award will go to someone who has had a distinguished career in the biotech or pharmaceutical arena, primarily within industry.
Winner:
Mads Øvlisen
NOMINEES:
HEADLINE SPONSOR
ICON plc is a world-leading healthcare intelligence and clinical research organisation, with over 38,000 employees in 93 locations in 46 countries around the world, headquartered in Dublin. We advance clinical research by providing outsourced development and commercialisation services to pharmaceutical, biotechnology, medical device, and government and public health organisations. Our services span the entire lifecycle of product development, from molecule to medicine, across a broad range of therapeutic areas. We develop new innovations, drive emerging therapies forward, and improve patient lives.
Leveraging our strong relationships, deep domain expertise, connected technology, and data intelligence we expand access, and enhance the quality, efficiency, and safety required to successfully advance research that saves and improves lives.
Avance Clinical offers clinical project management, trial monitoring, regulatory support, safety reporting, scientific and medical writing, data management, statistical and pharmacokinetic services, and external clinical auditing. We operate to the highest standards of compliance required by global regulatory agencies such as the FDA to ensure acceptance of data for drug approvals.
Our clients are international biotech companies in their early phases of drug development that require fast, agile, and adaptive solution-oriented clinical research services. The company uses state-of-the-art technology, gold standard systems, and deep scientific expertise to provide clients with the most successful outcomes.
The Avance Clinical team offers exceptional study approval and success rates which can be attributed to its deep scientific expertise, advanced data technologies, knowledge of the Australian, New Zealand and North American regulatory environment, and its extensive relationships with sites and KOLs.
